TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26568577

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation containing Lactobacillus casei (PRO)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 8
Study: 24798768

Group type: EXPERIMENTAL
Intervention: EFV-based HAART regimen
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: LPV/r-based HAART regimen
Number of subjects: 45

Group type: COMPARATOR
Intervention: non-HAART group
Number of subjects: 45
Study: 22414827

Group type: EXPERIMENTAL
Intervention: Monoject syringe with 27‐gauge needle
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Passive ultrasonic irrigation (PUI) with IrriSafe tip
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: EndoVac system
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Passive ultrasonic irrigation (PUI)
Number of subjects: 30
Study: 20373908

Group type: EXPERIMENTAL
Intervention: I-neb AAD System with Target Inhalation Mode (TIM)
Number of subjects: 12

Group type: COMPARATOR
Intervention: I-neb AAD System with Tidal Breathing Mode (TBM)
Number of subjects: 12
Study: 18575223

Group type: EXPERIMENTAL
Intervention: Adapalene 0.3% gel
Number of subjects: 551
Study: 16019647

Group type: EXPERIMENTAL
Intervention: Multi-source interference task (MSIT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flanker interference
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spatial interference
Number of subjects: 0
Study: 12449165

Group type: EXPERIMENTAL
Intervention: MPA (30 mg b.i.d.)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: ACET (250 mg b.i.d.)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: MPA/ACET
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: MPA
Number of subjects: 17
Study: 10211236

Group type: EXPERIMENTAL
Intervention: General practice teaching
Number of subjects: 225

Group type: COMPARATOR
Intervention: Teaching hospital
Number of subjects: 225
Study: 8523872

Group type: EXPERIMENTAL
Intervention: Carmeda BioActive Surface coated circuit
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Duraflo II bonded heparin coated circuit
Number of subjects: 67

Group type: COMPARATOR
Intervention: Uncoated circuit (control for Carmeda)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Uncoated circuit (control for Duraflo II)
Number of subjects: 67
Study: 1686197

Group type: EXPERIMENTAL
Intervention: Novel anxiolytic/hypnotic compound
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zolpidem
Number of subjects: 0

Group type: COMPARATOR
Intervention: Triazolam
Number of subjects: 0
Study: 7145555

Group type: EXPERIMENTAL
Intervention: High-dose split-product vaccine (SPV) containing 7, 7, and 60 micrograms of hemagglutinins (HA)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard dose split-product vaccine (SPV) containing 7, 7, and 7 micrograms of HA
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: High-dose split-product vaccine (SPV)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard dose split-product vaccine (SPV)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Unvaccinated matched sibling control subjects
Number of subjects: 80
Study: 31478938

Group type: COMPARATOR
Intervention: Nurse-controlled sedation (NCS) with midazolam
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Patient-controlled sedation (PCS) with propofol (PCS-MS group)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Patient-controlled sedation (PCS) with propofol (PCS-G group)
Number of subjects: 150
Study: 30529442

Group type: EXPERIMENTAL
Intervention: PROMIS Pain Interference scales
Number of subjects: 759

Group type: COMPARATOR
Intervention: Legacy pain measures (Brief Pain Inventory Interference scale; Pain, Enjoyment, General Activity scale; SF-36 Bodily Pain scale; Roland-Morris Disability Questionnaire)
Number of subjects: 759
Study: 28176175

Group type: EXPERIMENTAL
Intervention: WT1-immunotherapeutic
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard neoadjuvant therapy
Number of subjects: 62
Study: 26612050

Group type: EXPERIMENTAL
Intervention: Parental health literacy
Number of subjects: 1016
Study: 25148876

Group type: EXPERIMENTAL
Intervention: Long-term music-based multitask exercise program (Jaques-Dalcroze eurhythmics)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (discontinued participation)
Number of subjects: 52
Study: 21893151

Group type: EXPERIMENTAL
Intervention: 2-doses of PCV7(CRM197)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2+1-doses of PCV7(CRM197)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 20166437

Group type: EXPERIMENTAL
Intervention: Tramadol determination method using LC-MS
Number of subjects: 0
Study: 17449109

Group type: EXPERIMENTAL
Intervention: Lower CBCL externalizing scores
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Lower externalizing scores
Number of subjects: 91
Study: 14706012

Group type: EXPERIMENTAL
Intervention: Cholinergic therapy (bethanechol chloride 60 mg/day or distigmine bromide 15 mg/day)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Alpha-blocker therapy (urapidil 60 mg/day)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Combination therapy (cholinergic drug and alpha-blocker)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Cholinergic therapy (control)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Alpha-blocker therapy (control)
Number of subjects: 119
Study: 11676116

Group type: EXPERIMENTAL
Intervention: Butenafine (1%) cream applied for 4 weeks for tinea pedis and 2 weeks for tinea cruris and tinea corporis
Number of subjects: 111
Study: 11038765

Group type: EXPERIMENTAL
Intervention: Intraperitoneal (i.p.) carboplatin chemotherapy
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intravenous (i.v.) carboplatin chemotherapy
Number of subjects: 10
Study: 7946939

Group type: EXPERIMENTAL
Intervention: Oral isosorbide dinitrate (ISDN; 20 mg twice daily for 2 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3229341

Group type: EXPERIMENTAL
Intervention: Formula 1 (patient group 1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Formula 2 (patient group 2)
Number of subjects: 20
Study: 31838920

Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate for 4 weeks and a short course of oral steroids
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Clarithromycin for 8 weeks
Number of subjects: 57

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate
Number of subjects: 57

Group type: COMPARATOR
Intervention: Clarithromycin
Number of subjects: 57
Study: 28727270

Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg/day
Number of subjects: 620

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 620
Study: 26401752

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) (30 to 45 seconds)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Immediate cord clamping (ICC) (5 to 10 seconds)
Number of subjects: 40
Study: 25032112

Group type: EXPERIMENTAL
Intervention: marsupialisation + coblation
Number of subjects: 90

Group type: COMPARATOR
Intervention: marsupialisation + electric coagulation
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: marsupialisation + coblation + microsurgery
Number of subjects: 90
Study: 24397123

Group type: EXPERIMENTAL
Intervention: Traditional center of tibial plateau as the entry point (Group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Digital technology using Mimics 10.01 software for tibial intramedullary positioning (Group B)
Number of subjects: 60
Study: 19935070

Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 18079558

Group type: EXPERIMENTAL
Intervention: Prophylactic eccentric training and stretching of the Achilles and patellar tendons
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Prophylactic eccentric training and stretching of the patellar tendons
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Prophylactic eccentric training and stretching of the Achilles tendons
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Preseason ultrasonographic abnormalities in the tendons
Number of subjects: 209
Study: 16272199

Group type: EXPERIMENTAL
Intervention: Single-leg knee extensor exercise training for 6 weeks
Number of subjects: 11

Group type: COMPARATOR
Intervention: Cuff occlusion with superimposed handgrip exercise
Number of subjects: 11

Group type: COMPARATOR
Intervention: Baseline measurements (no intervention)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Post-training measurements (after exercise training)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Ischemic handgrip exercise after training
Number of subjects: 11
Study: 12730925

Group type: EXPERIMENTAL
Intervention: Patellar resurfacing during primary total knee arthroplasty
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patellar retention during primary total knee arthroplasty
Number of subjects: 0
Study: 11095598

Group type: EXPERIMENTAL
Intervention: Azithromycin (single dose)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Tetracycline (6-week course, twice daily)
Number of subjects: 314
Study: 9367292

Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 22
Study: 1454657

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 1.6 mg daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oral prednisone 10 mg daily
Number of subjects: 40
Study: 3922048

Group type: EXPERIMENTAL
Intervention: CaNa2EDTA infusion during the first 2 days after admission
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal conservative treatment
Number of subjects: 0
Study: 30352818

Group type: EXPERIMENTAL
Intervention: Circulating metabolites
Number of subjects: 4952

Group type: EXPERIMENTAL
Intervention: Genetic variables for fourteen top metabolites
Number of subjects: 4952

Group type: EXPERIMENTAL
Intervention: Metabolome
Number of subjects: 4952
Study: 30019751

Group type: EXPERIMENTAL
Intervention: Perioperative aspirin
Number of subjects: 603

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 603
Study: 26418211

Group type: EXPERIMENTAL
Intervention: HiP (high protein): parenteral nutrition = 3.5 AA, enteral nutrition = 4.6 protein g·kg·day
Number of subjects: 164

Group type: COMPARATOR
Intervention: StP (standard protein): parenteral nutrition = 2.5 AA, enteral nutrition = 3.6 protein g·kg·day
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: HiP
Number of subjects: 164

Group type: COMPARATOR
Intervention: StP
Number of subjects: 164
Study: 24500579

Group type: EXPERIMENTAL
Intervention: Hinged external fixator (Compass Knee Hinge) for six weeks (Group B)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ligament reconstruction with external hinged knee brace (Group A)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Hinged external fixator (Group B)
Number of subjects: 100

Group type: COMPARATOR
Intervention: External hinged knee brace (Group A)
Number of subjects: 100
Study: 22958175

Group type: EXPERIMENTAL
Intervention: DRD2 A1(‐) allele and/or DAT 9R(+) allele in sustained male quitters
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (continuing smokers)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DRD2 A1(+) allele and/or DAT 9R(‐) allele
Number of subjects: 0
Study: 21155337

Group type: EXPERIMENTAL
Intervention: Levobupivacaine-fentanyl (3 mg of 0.1% levobupivacaine plus 10 microg of fentanyl)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lidocaine-fentanyl (18 mg of 0.6% lidocaine plus 10 microg of fentanyl)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Levobupivacaine-fentanyl
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lidocaine-fentanyl
Number of subjects: 60
Study: 17602120

Group type: EXPERIMENTAL
Intervention: Conventional antipsychotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atypical antipsychotics
Number of subjects: 0
Study: 15295694

Group type: EXPERIMENTAL
Intervention: Canarypox HIV‐1 vaccine
Number of subjects: 1497

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1497
Study: 11256873

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 69
Study: 9831304

Group type: EXPERIMENTAL
Intervention: Naltrexone (75 mg daily for 12 weeks)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8085185

Group type: EXPERIMENTAL
Intervention: Self-help groups for relatives of schizophrenic patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (relatives not involved in self-help)
Number of subjects: 0
Study: 2751143

Group type: EXPERIMENTAL
Intervention: Oral medication (meperidine 3.0 mg/kg, pentobarbital 4.0 mg/kg)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Intramuscular medication (morphine 0.1 mg/kg, pentobarbital 4.0 mg/kg)
Number of subjects: 67
Study: 339373

Group type: EXPERIMENTAL
Intervention: Prazosin (Minipress; Pfizer)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 30948581

Group type: EXPERIMENTAL
Intervention: Messages sent on Tuesday
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Messages sent on Wednesday
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Messages sent on Thursday
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Messages sent on Friday
Number of subjects: 194

Group type: COMPARATOR
Intervention: Messages sent on Monday
Number of subjects: 194
Study: 29249224

Group type: EXPERIMENTAL
Intervention: MAKS therapy
Number of subjects: 362
Study: 26378264

Group type: EXPERIMENTAL
Intervention: Lower Extremity/Mobility Cerebral Palsy Computerized Adaptive Test (LE CP‐CAT)
Number of subjects: 255
Study: 23074076

Group type: EXPERIMENTAL
Intervention: Resistance training (RT) intervention for 8 weeks, 8 exercises, 1 set of 10 repetitions at perceived exertion of 5-6, performed twice a week
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 25
Study: 21110035

Group type: EXPERIMENTAL
Intervention: Uncinectomy (n = 10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Natural ostial dilatation (n = 10)
Number of subjects: 20
Study: 19709691

Group type: EXPERIMENTAL
Intervention: Intravenous glucose infusion (0.75 g glucose per kilogram body weight for 2.5 hours)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 17583027

Group type: EXPERIMENTAL
Intervention: Intervention group (12 family groups, 15 professionals)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control group (12 family groups, 14 professionals)
Number of subjects: 149
Study: 15716204

Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg daily for 4 weeks, followed by flexible dosing (5 mg or 10 mg)
Number of subjects: 1802

Group type: EXPERIMENTAL
Intervention: Solifenacin treatment
Number of subjects: 1802
Study: 12072586

Group type: EXPERIMENTAL
Intervention: 10 mg lercanidipine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 20 mg lercanidipine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 10 mg or 20 mg lercanidipine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 10086838

Group type: EXPERIMENTAL
Intervention: 1.0 mg reboxetine orally
Number of subjects: 12

Group type: COMPARATOR
Intervention: 0.3 mg reboxetine as an intravenous bolus
Number of subjects: 12
Study: 7985892

Group type: COMPARATOR
Intervention: Zidovudine, 600 mg/d
Number of subjects: 1001

Group type: COMPARATOR
Intervention: Zalcitabine, 2.25 mg/d
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: Zidovudine, 600 mg/d, and zalcitabine, 2.25 mg/d
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: Combination therapy (zidovudine and zalcitabine)
Number of subjects: 1001

Group type: COMPARATOR
Intervention: Zalcitabine
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: All treatment groups (for patients with 50 to 150 CD4 cells/mm3 or fewer than 50 CD4 cells/mm3)
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: Patients with 150 or more CD4 cells/mm3
Number of subjects: 1001
Study: 2154407

Group type: EXPERIMENTAL
Intervention: Enalapril (initial dose, long-term treatment for 1 and 6 weeks)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Enalapril (after first dose)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Enalapril (after 1 week)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Enalapril (after 6 weeks)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 380178

Group type: EXPERIMENTAL
Intervention: diethylpropion hydrochloride (Tenuate)
Number of subjects: 40

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study: 31809270

Group type: EXPERIMENTAL
Intervention: LA‐PM&R
Number of subjects: 2222

Group type: COMPARATOR
Intervention: Control (non-participants)
Number of subjects: 2222
Study: 31816842

Group type: EXPERIMENTAL
Intervention: Euglena gracilis fermentate (BG) 367 mg
Number of subjects: 34
Study: 28062085

Group type: EXPERIMENTAL
Intervention: ThuLEP
Number of subjects: 208

Group type: COMPARATOR
Intervention: TURis
Number of subjects: 208
Study: 25816702

Group type: EXPERIMENTAL
Intervention: SMS reminder system for OGTT at six weeks postpartum with further reminders at three and six months if required.
Number of subjects: 276

Group type: COMPARATOR
Intervention: Control group received one text reminder at six months postpartum.
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: SMS reminder system for OGTT at six weeks postpartum.
Number of subjects: 276
Study: 24216113

Group type: EXPERIMENTAL
Intervention: Affected meridian acupuncture group (n = 107)
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Non-affected meridian acupuncture group (n = 107)
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Invasive sham acupuncture group (n = 107)
Number of subjects: 428

Group type: COMPARATOR
Intervention: Waiting-list group (n = 107)
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: All acupuncture groups
Number of subjects: 428
Study: 21297128

Group type: EXPERIMENTAL
Intervention: Pre-RT MRI parameters (T2 hyperintensity lesion volume, nonenhancing lesion volume)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Post-RT MRI parameters (normalized cerebral blood volumes, normalized peak height, normalized recirculation factors)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Change in MRI parameters from pre-RT to post-RT (nCBV, nPH, ADC)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Pre-RT nRF values
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Change in nRF from pre-RT to post-RT
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Patterns of changes in ADC and anatomic volumes
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Changes in nCBV, nPH, and contrast-enhancing volume
Number of subjects: 64
Study: 19133058

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 17845651

Group type: EXPERIMENTAL
Intervention: Albumin 5%
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 4% modified gelatine solution
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch 130/0.4 (HES)
Number of subjects: 42
Study: 15218813

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate treatment over 3 years
Number of subjects: 943
Study: 11451751

Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg daily for 6 weeks)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 5-methyltetrahydrofolate (5-MTHF)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Folic acid and tetrahydrobiopterin (in vitro)
Number of subjects: 52
Study: 9712496

Group type: EXPERIMENTAL
Intervention: Bone marrow supplemented with allogeneic peripheral blood cells collected by apheresis after stimulation with filgrastim
Number of subjects: 27

Group type: COMPARATOR
Intervention: Bone marrow alone
Number of subjects: 27
Study: 2563695

Group type: EXPERIMENTAL
Intervention: Short course metronidazole rectal suppositories
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study: 1097098

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: mitomycin C
Number of subjects: 25

Group type: COMPARATOR
Intervention: untreated historical controls
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: catheterized patients
Number of subjects: 25
Study: 30640644

Group type: EXPERIMENTAL
Intervention: Distributed randomized gradient-free optimization protocol
Number of subjects: 0
Study: 30664487

Group type: EXPERIMENTAL
Intervention: eMums Plus intervention delivered via mobile phone app
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 160
Study: 28716656

Group type: EXPERIMENTAL
Intervention: 40mg atomoxetine
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 80mg atomoxetine
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 26063503

Group type: EXPERIMENTAL
Intervention: Clopidogrel 300/75 mg regimen
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Clopidogrel 600/150 mg regimen
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Clopidogrel 300/75 mg regimen and 600/150 mg regimen
Number of subjects: 72
Study: 23151750

Group type: EXPERIMENTAL
Intervention: Usual MAP treatment goal (102‐107 mm Hg)
Number of subjects: 828

Group type: EXPERIMENTAL
Intervention: Low MAP treatment goal (≤92 mm Hg)
Number of subjects: 828

Group type: EXPERIMENTAL
Intervention: Amlodipine in usual MAP group
Number of subjects: 828

Group type: EXPERIMENTAL
Intervention: Amlodipine in low MAP group
Number of subjects: 828
Study: 21722694

Group type: EXPERIMENTAL
Intervention: S. salivarius K12 (1 × 10(10) cfu) for 28 days
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo for 28 days
Number of subjects: 53
Study: 18485575

Group type: EXPERIMENTAL
Intervention: Cizolirtine citrate 400 mg bid (C400)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Cizolirtine citrate 200 mg bid (C200)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 17018196

Group type: EXPERIMENTAL
Intervention: Whole-systems self-management approach using a guidebook developed with patients and physicians trained in patient-centred care.
Number of subjects: 651

Group type: COMPARATOR
Intervention: Usual treatment (control group).
Number of subjects: 651

Group type: EXPERIMENTAL
Intervention: Whole-systems self-management approach.
Number of subjects: 651